Clinical Trial Update: PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating palmitoylethanolamide (PEA) for relief of chemotherapy-induced peripheral neuropathy; study is active-not-recruiting with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Peripheral Neuropathy
• Hematologic Malignancies
• Solid Tumors

Drugs mentioned

• Palmitoylethanolamide (PEA) (palmitoylethanolamide)

Snippet

Sponsor: Academic and Community Cancer Research United | Conditions: Chemotherapy-Induced Peripheral Neuropathy, Hematopoietic and Lymphoid Cell Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-01-24